Results 21 to 30 of about 37,793 (186)

A Potential Practical Process for Remdesivir

, 2021
A four-step synthesis of Remdesivir (1) is presented. This work focuses on the yield improvement of step 1, flow chemistry development of step 2 and 3, process optimization of step 4.
Miao, Wu, Jinguang, Liu, Jianye, Jiao, Xin, Zhang, Han, Lin, Liujuan, Chen, Chen, Liujuan, Guowei, Zhang   +7 more
core   +1 more source

The efficacy and safety of remdesivir alone and in combination with other drugs for the treatment of COVID-19: a systematic review and meta-analysis

BMC Infectious Diseases, 2023
Background Remdesivir is considered to be a specific drug for treating coronavirus disease 2019. This systematic review aims to evaluate the clinical efficacy and risk of remdesivir alone and in combination with other drugs.
Chuizhe Chen, Junde Fang, Shu Chen, Mamy Jayne Nelly Rajaofera, Xuemiao Li, Bo Wang, Qianfeng Xia   +6 more
doaj   +1 more source

Impact of Remdesivir Incorporation Along the Primer Strand on SARS-CoV-2 RNA-dependent RNA polymerase

, 2022
Remdesivir was the first antiviral drug that received emergency use authorization from the United States Food and Drug Administration and is now formally approved to treat COVID-19.
Sehr, Naseem-Khan, Madison B., Berger, Emmett M., Leddin, G. Andrés, Cisneros, Yazdan , Maghsoud   +4 more
core   +1 more source

Effects of Remdesivir on in-Hospital and Late Outcomes of Patients With Confirmed or Clinically Suspected COVID-19: A Propensity Score-Matched Study

Acta Medica Iranica, 2022
Remdesivir, an antiviral medication, became an early promising therapeutic candidate for coronavirus disease 2019 (COVID-19) due to its ability to inhibit the virus in vitro. Current evidence about remdesivir treatment has been very controversial, so we
Azar Hadadi, Ali Ajam, Mahnaz Montazeri, Samira Kafan, Abdolazim Veisizadeh, Morteza Ghoghaei, Sina Kazemian, Arezoo Ahmadi, Fazeleh Majidi, Maryam Moghadasi, Mehdi Kashani, Faezeh Ghasemi, Marzieh Pazoki   +12 more
doaj   +1 more source

1’-cyano substitution of Remdesivir “template-dependent” inhibiting the transcription of SARS-CoV-2

, 2022
Remdesivir is one nucleotide analog prodrug capable to terminate RNA synthesis in SARS-CoV-2 RdRp by two distinct mechanisms. The “delayed chain termination mechanism” has been extensively investigated, while the “template-dependent inhibition mechanism”
Xueying, Luo, Xin, Gao, Lu, Zhang, Xiaowei, Wang   +3 more
core   +1 more source

An open-label, randomized, single intravenous dosing study to investigate the effect of fixed-dose combinations of tenofovir/lamivudine or atazanavir/ritonavir on the pharmacokinetics of remdesivir in Ugandan healthy volunteers (RemTLAR)

Trials, 2021
Background Remdesivir is a novel broad-spectrum antiviral therapeutic with activity against several viruses that cause emerging infectious diseases.
Stephen I. Walimbwa, Julian P. Kaboggoza, Catriona Waitt, Pauline Byakika-Kibwika, Antonio D’Avolio, Mohammed Lamorde   +5 more
doaj   +1 more source

Revisiting Hydrazine Moiety as a Scaffold for the Synthesis of Potential Antiviral Pyrazole Ribonucleoside Analogues. [PDF]

ChemMedChem
Three series of pyrazole ribonucleoside analogues were designed and synthesized. They were evaluated, along with some of their pronucleotides, for their antiviral activity against RNA viruses. Pyrazole ribonucleoside analogues were prepared via a linear approach starting with the reaction of D‐ribosylhydrazine with 1,3‐dicarbonyl or acrylonitrile ...
Guillou A, Gros N, Muriaux D, Peyrottes S, Vasseur JJ, Smietana M, Mathé C.   +6 more
europepmc   +2 more sources

Total synthesis of remdesivir

, 2022
Remdesivir, the first drug approved by the FDA to treat COVID-19, is in high demand for patients infected with the SARS-CoV-2 virus. Herein, we report a facile approach minimizing the protecting group manipulations to afford remdesivir in good overall ...
Krishna Avula, Shiva, Chandrasekhar, Srivari, Ghosh, Subhash, Mainkar, Prathama S., Sridhara Shanmukha Rao, B., Kumar Palli, Kishore, Raji Reddy, Chada, Ghosh, Palash, Sudhakar, Gangarajula, Patil, Amol D.   +9 more
core   +1 more source

Cardiovascular events and safety outcomes associated with remdesivir using a World Health Organization international pharmacovigilance database

Clinical and Translational Science, 2022
On October 2020, the US Food and Drug Administration (FDA) approved remdesivir as the first drug for the treatment of coronavirus disease 2019 (COVID‐19), increasing remdesivir prescriptions worldwide.
Se Yong Jung, Min Seo Kim, Han Li, Keum Hwa Lee, Ai Koyanagi, Marco Solmi, Andreas Kronbichler, Elena Dragioti, Kalthoum Tizaoui, Sarah Cargnin, Salvatore Terrazzino, Sung Hwi Hong, Ramy Abou Ghayda, Nam Kyun Kim, Seo Kyoung Chung, Louis Jacob, Joe‐Elie Salem, Dong Keon Yon, Seung Won Lee, Karel Kostev, Ah Young Kim, Jo Won Jung, Jae Young Choi, Jin Soo Shin, Soon‐Jung Park, Seong Woo Choi, Kiwon Ban, Sung‐Hwan Moon, Yun Young Go, Jae Il Shin, Lee Smith   +30 more
doaj   +1 more source

High-throughput rational design of the remdesivir binding site in the RdRp of SARS-CoV-2: implications for potential resistance

iScience, 2021
Summary: The use of remdesivir to treat COVID-19 will likely continue before clinical trials are completed. Due to the lengthening pandemic and evolving nature of the virus, predicting potential residues prone to mutation is crucial for the management of
Aditya K. Padhi, Rohit Shukla, Prakash Saudagar, Timir Tripathi   +3 more
doaj   +1 more source